Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Physician diagnosis of asthma for ≥6 months~* Pre-bronchodilator FEV1 of \>40% and \<80%~* History of treatment with corticosteroid or hospitalization for worsening asthma~* Medium- or high-dose inhaled corticosteroid use~Exclusion Criteria:~* History of smoking/vaping~* History of severe COVID~* Serious and/or uncontrolled pulmonary, cardiac, immune system conditions~* Requires systemic oral or IV corticosteroids in the month prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RPT193 400 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).